Daiichi Sankyo Company, Limited (DSKYF)
| Previous close | 30.30 |
| Open | 29.42 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 29.42 - 30.78 |
| 52-week range | 23.45 - 37.91 |
| Volume | |
| Avg. volume | 20,185 |
| Market cap | 58.383B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 48.33 |
| EPS (TTM) | 0.63 |
| Earnings date | N/A |
| Forward dividend & yield | 0.40 (1.30%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | 35.94 |
ZacksAtossa (ATOS) Reports Positive Results From EVANGELINE Study
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
ZacksMerck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
BenzingaAstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
On Friday, the FDA approved Daiichi Sankyo Ltd’s (OTC:DSKYF) (OTC:DSNKY) and AstraZeneca Plc’s (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indicat
